MORE HERE:
(EXCERPT)
Dr Frank Grosveld, the study’s other co-lead author, said the discovery provided “a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment”.
“The antibody used in this work is ‘fully human’, allowing development to proceed more rapidly and reducing the potential for immune-related side effects,” he added.
The fully-human antibody is different from conventional therapeutic antibodies, which are often first developed in other species before being “humanised” so they can be transmitted to people.
It was developed using Harbour BioMed’s H2L2 transgenic mouse technology - effectively a mouse which has been genetically engineered to contain human genes, enabling researchers to develop “human” antibodies without testing them on living people.
“This is groundbreaking research,” said Dr Jingsong Wang, the chief executive of HBM.
bkmk!
Will Dr. Goebbels object and call it anecdotal?